Nasdaq:US$13.76 (+0.02) | HKEX:HK$22.10 (+0.30) | AIM:£2.12 (+0.05)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases, Oncology / Immunology | 29 Feb 2008

Chi-Med Announces Start of Patient Enrolment in a Global Phase IIb Ulcerative Colitis Clinical Trial of HMPL-004, its Leading Anti-Inflammatory Drug Candidate

1 items
a080229